Stent Specifically Designed to Prevent Restenosis


June 30, 2006

Using a closed-cell design, the CYPHER stent delivers sirolimus, a drug that selectively targets and interrupts proliferating cells early in the cell cycle, halting the development of neointimal hyperplasia while allowing natural healing and normal re-endothelialization. It is available in over-the-wire and rapid exchange delivery systems. It comes in 8, 13, 18, 28 and 30 mm lengths and has radio-opaque markers.